MOMA-313 is under clinical development by Moma Therapeutics and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MOMA-313’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MOMA-313 overview
MOMA-313 is under development for the treatment of solid tumors including metastatic breast cancer, metastatic pancreatic cancer, metastatic prostate cancer. It acts by targeting DNA polymerase theta. It is administered by oral route.
Moma Therapeutics overview
Moma Therapeutics is a biopharmaceutical company that discovers novel precision medicines to treat patients with unmet medical needs. The company is developing a drug discovery platform that considers both molecular and genetic attributes to identify the molecular machines or enzymes that drive disease. Its drug discovery platform harnesses advancements in genetics and functional genomics to unlock the potential of molecular machines and advance the treatment for various types of cancer and cystic fibrosis. Moma Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MOMA-313’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
